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Prenatal stem cell-based regenerative therapies have progressed substantially and have been demonstrated as effective treatment
options for fetal diseases that were previously deemed untreatable. Due to immunoregulatory properties, self-renewal capacity,
and multilineage potential, autologous human placental chorionic villus-derived mesenchymal stromal cells (CV-MSCs) are an
attractive cell source for fetal regenerative therapies. However, as a general issue for MSC transplantation, the poor survival and
engraftment is a major challenge of the application of MSCs. Particularly for the fetal transplantation of CV-MSCs in the
naturally hypoxic fetal environment, improving the survival and engraftment of CV-MSCs is critically important. Hypoxic
preconditioning (HP) is an effective priming approach to protect stem cells from ischemic damage. In this study, we developed
an optimal HP protocol to enhance the survival and proangiogenic capacity of CV-MSCs for improving clinical outcomes in
fetal applications. Total cell number, DNA quantification, nuclear area test, and cell viability test showed HP significantly
protected CV-MSCs from ischemic damage. Flow cytometry analysis confirmed HP did not alter the immunophenotype of CV-
MSCs. Caspase-3, MTS, and Western blot analysis showed HP significantly reduced the apoptosis of CV-MSCs under ischemic
stimulus via the activation of the AKT signaling pathway that was related to cell survival. ELISA results showed HP significantly
enhanced the secretion of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) by CV-MSCs under
an ischemic stimulus. We also found that the environmental nutrition level was critical for the release of brain-derived
neurotrophic factor (BDNF). The angiogenesis assay results showed HP-primed CV-MSCs could significantly enhance
endothelial cell (EC) proliferation, migration, and tube formation. Consequently, HP is a promising strategy to increase the
tolerance of CV-MSCs to ischemia and improve their therapeutic efficacy in fetal clinical applications.
1. Introduction
Over the past three decades, with the development and
exciting advances of fetal surgery for treatment of congenital
diseases, fetal tissue engineering has been established as an
emerging field of fetal medicine to augment in utero surgical
approaches [1–3]. Mesenchymal stem cells (MSCs) are
multipotent stem cells with the ability to self-renew and
have been isolated from various tissues, such as the bone
marrow [4], heart [5], adipose [6], peripheral blood [7],
dental pulp [8], cord blood [9], menstrual blood [10–12],
Wharton’ s jelly [13], and chorionic villi [14]. They have
the potential to differentiate into the bone, cartilage, fat,
and muscle [15, 16]. Therefore, MSCs are a promising
source for the cellular treatment of a variety of congenital
diseases. However, allogeneic MSC treatment for congenital
diseases has generally shown limited long-term engraftment
after transplantation [17, 18].
In contrast to the postnatal environment, the fetal
environment contains numerous characteristics that may
allow for the improvement of stem cell-based therapies;
therefore, prenatal cellular transplantation is a promising
approach for treating a variety of congenital anomalies. The
fetal environment is advantageous for stem cell engraftment
because it is naturally receptive to remodelling and regenera-
tion of fetal tissues by stem cells and it is highly conducive to
expansion of stem cell compartments [19–23]. Ideally, trans-
planting autologous fetal stem cells should endow long-term
engraftment, even after the baby is born [19, 20, 24]. In con-
sideration of autologous fetal cell sources, however, collection
of fetal blood and tissues is technically challenging due to the
risk of fetal demise [25–27] and the routine availability of
amniocentesis only in the second trimester [28–30]. The pla-
centa is a promising autologous MSC source [31, 32], as cho-
rionic villus sampling (CVS) can be performed in early
gestation to obtain fetal stem cells. It has been shown that first
trimester fetal MSCs possess several advantages for regenera-
tive medicine over adult and perinatal MSCs [33–37]. There-
fore, isolation of MSCs from first trimester chorionic villus
tissue (CV-MSCs) that allows for therapeutic use for in utero
applications represents a promising approach for autologous
fetal treatment of birth defects [38].
In our previous studies, we have successfully estab-
lished the CV-MSC isolation protocol [39] and treated
some fetal diseases using CV-MSCs, such as spina bifida
[40–42] and hemophilia [43, 44]. However, another limi-
tation to the stem cell therapeutic efficiency is the poor
survival of transplanted cells in ischemic target tissue
[45, 46]. Most implanted cells may die within several
days after transplantation, partially due to the drastic
environmental changes [47]. Thus, improving cell engraft-
ment efficiency after transplantation is critical for enhancing
stem cell therapeutic efficiency. Several strategies have been
designed to solve this problem, such as preconditioning of
the cells by oxidative stress, heat shock, and hypoxia [48].
In all of these instances, hypoxic preconditioning (HP) is
the best approach to protect stem cells from ischemic damage
in animal models [49, 50] and has also been shown to
increase protective effects of MSCs on different types of
ischemic target tissue [51–54]. However, whether hypoxic
preconditioning could enhance autologous CV-MSC-based
treatment of fetal diseases has not yet been determined.
Angiogenesis is also essential for tissue development,
maintenance, and regeneration to improve therapeutic effi-
ciency in fetal regeneration [55]. Angiogenesis can be
stimulated by multiple angiogenic cytokines, such as vascular
endothelial growth factor (VEGF), brain-derived neuro-
trophic factor (BDNF), and hepatocyte growth factor
(HGF), secreted from transplanted MSCs [56]. Thus,
enhancing the proangiogenic ability of transplanted CV-
MSCs will further improve the therapeutic effects of the
transplanted cells. In this study, to further improve the ther-
apeutic potential of CV-MSCs for the treatment of fetal
diseases, we aimed to develop an optimal HP protocol to
enhance survival and proangiogenic capacity of transplanted
autologous CV-MSCs for future clinical applications, in
treating a variety of fetal diseases.
2. Materials and Methods
2.1. Cell Isolation and Culture. Human placental tissues
(n = 4) from the first trimester gestation (≤12 weeks of
gestation) were collected from healthy consenting patients
during elective abortions at the UC Davis Medical Center,
with approval from the Institutional Review Board. CV-
MSCs were isolated from chorionic villus tissue using an
explant culture method previously established in our lab
[39, 41, 57–59]. Chorionic villus tissue was washed in
phosphate-buffered saline (PBS, Cat. No.: SH3025601,
HyClone) containing 100U/mL penicillin and 100 μg/mL
streptomycin (1% pen-strep, Cat. No.: 15070063, Thermo
Fisher Scientific) and dissected into smaller pieces. Tissues
were evenly spread across tissue culture-treated flasks and
cultured in D5 media containing high-glucose DMEM
(Cat. No.: SH3028401, HyClone), 5% fetal bovine serum
(FBS, Cat. No.: SH30071.03, HyClone), 20 ng/mL recombi-
nant human basic fibroblast growth factor (bFGF, Cat.
No.: 233-FB, R&D systems), and 20ng/mL recombinant
human epidermal growth factor (EGF, Cat. No.: 236-EG,
R&D systems) and incubated at 37°C, 5% CO2. Cells were
allowed to migrate from the tissue and grow to 80-90%
confluency before the first passage. The media was changed
every 3-4 days. CV-MSCs were used between P3 and P5 for
all experiments.
2.2. Hypoxic Preconditioning and Simulated Ischemia. The
whole experimental process was depicted in Figure 1. For
HP, CV-MSCs were subjected to a hypoxic condition with
1% O2 and 5% CO2, achieved by replacing O2 with N2 in
an O2- and CO2-controlled multigas incubator (Coy Labo-
ratory Products Inc.), while being kept in D5 media. CV-
MSCs were incubated under normoxic conditions with
21% O2 and 5% CO2 in D5 media serving as control
(non-HP). For simulated ischemia, CV-MSCs were sub-
jected to the 1% O2, 5% CO2 in glucose-free DMEM
(Cat. No.: A14430-01, Thermo Fisher Scientific) without
FBS or growth factors which has been widely used for
in vitro studies to mimic the ischemic environment in vivo
[60, 61]. After ischemic stimulus, the cells were detached
using TrypLE (Cat. No.: 12563029, Gibco), and total cell
number was determined using Trypan Blue (Cat. No.:
15250061, Thermo Fisher Scientific). Total DNA was deter-
mined using the Quant-iT PicoGreen dsDNA kit (Cat. No.:
P7589, Thermo Fisher Scientific). Cell nucleus was stained
by DAPI (4′,6-diamidino-2-phenylindole dihydrochloride)
(Cat. No.: D3571, Thermo Fisher Scientific) and imaged
using an Olympus IX81 microscope. Nuclear area was quan-
tified using ImageJ software (NIH). Cell viability test was
performed using a LIVE/DEAD® Fixable Aqua Dead Cell
Stain Kit (Cat. No.: L34957, Thermo Fisher Scientific), and
the results were imaged using the Olympus IX81 microscope
and quantified using ImageJ software.
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2.3. Flow Cytometry Analysis. CV-MSCs at passage 5 were
detached using Accutase (Cat. No.: A1110501, Thermo
Fisher Scientific) and divided into 1 × 106 cells per sample
for assessment by flow cytometry. Expression of surface
markers was analyzed using the following antibodies:
FITC-CD44 (Cat. No.: 560977, clone G44-26), PE-CD90
(Cat. No.: 561970, clone 5E10), PE-CD73 (Cat. No.:
561014, clone AD2), APC-CD105 (Cat. No.: 562408, clone
266), APC-CD29 (Cat. No.: 561794, clone MAR4), PE-
CD34 (Cat. No.: 550761, clone 563), PE-CD31 (Cat. No.:
560983, WM59), APC-CD45 (Cat. No.: 560973, clone
HI30), and appropriate isotype controls including PE-Ms
IgG1 k (Cat. No.: 556650, clone MOPC-21), APC-Ms
IgG1 k (Cat. No.: 550854, clone MOPC-21), and FITC-Ms
IgG2b k (Cat. No.: 556655, clone 27-35) (all from BD
Biosciences). Cells were fixed in 10% formalin (Cat. No.:
SF-100, Thermo Fisher Scientific) for 30 minutes prior to
analysis and were analyzed on a BD LSRFortessa cell ana-
lyzer, and further data analysis and gating were performed
using FlowJo software (FlowJo, LLC). The flow cytometry
analysis gating strategy was as follows: CV-MSCs were
based on size and density from forward and side scatter.
From the CV-MSC population, single cells were then gated
based on forward scatter height verse forward scatter area.
From the single cell populations of CV-MSCs, live cells
were further gated using the exclusion viability dye NearIR
(Cat. No.: L34975, Thermo Fisher Scientific). Phenotypes
were determined using isotype controls for each respective
fluorophore. Gating on isotypes was determined to be less
that 1 percent positive.
2.4. Evaluation of CV-MSC Survival. CV-MSCs were seeded
in 96-well plates (15,000 cells/cm2) with three independent
samples in duplicates. After HP and ischemic stimulus, the
cells were lysed and analyzed by caspase-3 assay using a
Caspase-3 Activity Assay Kit (Cat. No.: 5723, Cell Signaling
Technology) according to the manufacturer’s instruction.
Fluorescence (ex 380nm/em 450nm) was measured using a
SpectraMax i3x Multi-Mode Detection Platform (Careforde
Safety & Scientific). The cells also were determined using a
CellTiter 96® AQueous One Solution Cell Proliferation Assay
(MTS, Cat. No.: G3582, Promega) according to the manufac-
turer’s instruction. The amount of soluble formazan product
produced by the reduction of MTS by metabolically active
cells was measured at the 490nm absorbance using the
SpectraMax i3x Multi-Mode Detection Platform.
2.5. Western Blot Analysis. After HP and ischemic stimulus,
cells were washed with DPBS and lysed in lysis buffer con-
taining RIPA lysis buffer (Cat. No.: 89901, Thermo Fisher
Scientific), sodium metavanadate (Cat. No.: sc-251034,
NaVO3, Santa Cruz Biotechnology), PMSF (Cat. No.:
36978, Thermo Fisher Scientific), and protease and phos-
phatase inhibitor cocktail (Cat. No.: 78440, Thermo Fisher
Scientific). Protein concentration was determined by
bicinchoninic acid (BCA) protein assay (Cat. No.: 23227,
Thermo Scientific); denatured protein was resolved in a
NuPAGE™ 4-12% Bis-Tris Protein Gel (Cat. No.:
NP0323, Thermo Fisher Scientific) and transferred to a
nitrocellulose membrane (Cat. No.: 77012, Thermo Fisher
Scientific). Membranes were blocked and incubated
overnight at 4°C with primary antibodies against AKT
(Cat. No.: 9272, Cell Signaling Technology), phospho-
AKT (Cat. No.: 4060, Cell Signaling Technology), and
GAPDH (Cat. No.: sc-32233, Santa Cruz Biotechnology).
Subsequently, membranes were incubated for 1 h with
conjugated secondary antibodies (Cat. No.: 7074, Cell Sig-
naling Technology) at room temperature and blots were
imaged using a ChemiDoc MP+ imaging system (Bio-
Rad), and further data analysis and gating were performed
using ImageJ software.
(i) 1% O2, 5% CO2, 
(ii) DMEM (Glc+, FBS+, GFs+)HP
(i) 21% O2, 5% CO2, 
(ii) DMEM (Glc+, FBS+, GFs+)Non-HP
Survival
Secretion
(i) CV-MSC functions
(i) EC functions
Proliferation
Migration
Tube formation
Simulated ischemia: 
1% O2, 5% CO2, 
DMEM (Glc–, FBS–, GF–)
24 h 24 h
Figure 1: The whole experimental process. CV-MSCs were treated with HP or non-HP for 24 h, then the pretreated CV-MSCs were
transferred to a simulated ischemic environment for another 24 h. The survival and secretion of CV-MSC were determined. The effects of
condition media obtained from CV-MSCs after ischemic stimulus on EC proliferation, migration, and differentiation were evaluated.
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2.6. Cytokine Secretion of CV-MSCs. To determine the effect
of the hypoxic condition on CV-MSC secretion, CV-MSCs
were seeded in 96-well plates (15,000 cells/cm2) with three
independent samples in duplicates and cultured in D5
media under hypoxic condition with 1% O2 or normoxic
condition with 21% O2. To determine the effect of HP
on CV-MSC secretion under ischemic stimulus, CV-
MSCs were seeded in 96-well plates (15,000 cells/cm2)
with three independent samples in duplicates and cultured
in D5 media under hypoxic condition with 1% O2 or nor-
moxic condition with 21% O2 for 24 h. The cells were then
transferred and subjected to the 1% O2 in glucose-free
DMEM without FBS or growth factors. Supernatants were
collected and analyzed by ELISA using individual VEGF
(Cat. No. DVE00, R&D Systems), HGF (Cat. No.
DHG00B, R&D Systems), or BDNF (Cat. No. DBD00,
R&D Systems) ELISA kit according to the manufacturer’s
instructions. The data was collected at 450nm absorbance
using a SpectraMax i3x Multi-Mode Detection Platform.
2.7. Proangiogenic Capacity of CV-MSCs. Conditioned media
collected from CV-MSCs with HP or non-HP after ischemic
stimulus were centrifuged at 10000 rpm for 10min to remove
floating cells and debris. For survival experiments, human
endothelial colony forming cells (HECFCs) were seeded in
96-well plates (20000 cells/cm2) with three independent
samples in duplicates and cultured in the conditioned media
for 5 days. The media were changed every other day. The via-
ble cell number was determined at different time points using
MTS assay. For migration experiments, HECFCs were seeded
in Culture-Insert 2 Well in μ-Dish (Cat. No.: 81176, ibidi)
with three independent samples in duplicates and cultured
in the conditioned media for 12 h. Images were taken using
a Carl Zeiss Axio Observer D1 inverted microscope. The
cell-covered area was quantified using ImageJ software. For
tube formation experiments, HECFCs were seeded in 96-
well plates precoated with 50 μL Matrigel (Cat. No.: 354234,
Corning) according to the manufacturer’s instructions at a
density of 104 cells/well with three independent samples in
duplicates and cultured in the conditioned media. After
12 h, cells were observed using the Carl Zeiss Axio Observer
D1 inverted microscope. The total segment tube length was
quantified using ImageJ software.
2.8. Statistical Analysis. For two-sample comparison,
Student’s t-test was used. For multiple-sample comparison,
the significance of intergroup differences was tested by one-
way analysis of variance (ANOVA), and Tukey’s multiple
comparisons test was used for postanalysis. A p value of
0.05 or less indicates significant difference between samples
in comparison.
3. Results
3.1. HP Protected CV-MSCs from Ischemic Damage. Prior to
ischemic stimulus, CV-MSCs with HP and CV-MSCs with
non-HP were, respectively, cultured in 1% O2 and D5
medium or 21% O2 and D5 medium for 12h, 24 h, 36 h, or
48 h. Both CV-MSCs with HP and CV-MSCs with non-HP
were then cultured in the ischemic environment for 24 h. In
addition to cell viability, alteration in nuclear morphology
is another important indication in apoptotic cells. The
nuclear morphology in injured or dead cells generally falls
into nuclear condensation: a decrease in nuclei size without
chromatin margination [62]. In this study, we evaluated the
cell viability using three different approaches and assessed
the nuclear morphology by DAPI staining and fluorescence
microscopy. The results of remaining viable cell number
(Figure 2(a)), total DNA (Figure 2(b)), nuclear area
(Figure 2(c)), and cell viability (Figure 2(d)) uniformly
showed that ischemic damage of CV-MSCs was significantly
reduced after shorter or longer HP periods, and the 24h HP
proved the most efficient. Statistical analysis was performed
between each group, and the results showed significant
differences among all the hypoxic preconditioning groups
(12 h, 24 h, 36 h, and 48 h) and the control group (0 h), but
no significant differences among the hypoxic precondition-
ing groups (12 h, 24 h, 36 h and 48h).
3.2. HP Did Not Alter the Immunophenotype of CV-MSCs.
In order to evaluate if HP altered the immunophenotype
of CV-MSCs, we characterized the CV-MSCs cultured in
the hypoxic environment (1% O2, DMEM with glucose,
FBS, and GFs) for 24 h (CV-MSCs with HP) and the CV-
MSCs cultured in the normoxic environment (21% O2,
DMEM without glucose, FBS, and GFs) for 24 h (CV-MSCs
with non-HP) by using flow cytometry analysis, which was
shown in the first 24 h section in the diagram (Figure 1).
The results displayed profiles of both the CV-MSCs with
HP and the CV-MSCs with non-HP which were positive
for well-established MSC markers CD29, CD44, CD73,
CD90, and CD105 [63], whereas they were negative for
hematopoietic and endothelial-related markers CD31,
CD34, and CD45 (Figure 3). The percentage of immuno-
phenotype of CV-MSCs with HP and CV-MSCs with
non-HP is shown in Table 1. There is no significant differ-
ence between the two groups. These results demonstrated
that HP did not alter the immunophenotype of CV-MSCs.
3.3. HP Reduced Apoptosis of CV-MSCs under Ischemic
Stimulus via Activated Related Biological Signals. To
determine the effect of HP on CV-MSC apoptosis under
ischemic stimulus, microphotographs taken by light micros-
copy showed that CV-MSCs with HP (Figure 4(a), B) were
healthier than CV-MSCs with non-HP after ischemic stimu-
lus (Figure 4(a), A). Caspase-3 assay and MTS assay were
performed to further confirm the effect of HP on CV-MSC
apoptosis after ischemic stimulus. The results showed that
caspase-3 activity in CV-MSCs with HP was significantly less
than that measured in CV-MSCs with non-HP (Figure 4(b)).
The MTS assay results showed HP significantly enhanced
CV-MSC survival after ischemic stimulus (Figure 4(c)). The
activation of AKT does not only inhibit the proapoptotic
factors but also activates the transcription of antiapoptotic
genes, which are involved in the regulation of the key cellular
functions including cell growth and survival [64]. Our subse-
quent Western blot data showed that the activated form of
AKT, phosphorylated-AKT (p-AKT), expressed in CV-
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Figure 2: HP reduced ischemic damage of CV-MSCs. Cell number (a), total DNA (b), nuclear area (c), and cell viability (d) of CV-MSCs
pretreated with HP or non-HP for 0 h, 12 h, 24 h, 36 h, or 48 h and followed by 24 h cultivation under ischemic stimulus. Data are
expressed as mean ± standard deviation: ∗p < 0:05 and ∗∗p < 0:01 (n = 4).
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Figure 3: Immunophenotype of CV-MSCs with HP and CV-MSCs with non-HP. Flow cytometry results displayed profiles of both the
CV-MSCs with HP (a) and the CV-MSCs with non-HP (b) which were positive for markers CD29, CD44, CD73, CD90, and CD105,
whereas they were negative for markers CD31, CD34, and CD45.
Table 1: Percentage of immunophenotype of CV-MSCs with HP and CV-MSCs with non-HP.
CD29 CD44 CD73 CD90 CD105 CD31 CD34 CD45
HP 99:6 ± 0:08% 99:0 ± 0:1% 99:4 ± 0:03% 99:8 ± 0:06% 98:5 ± 0:08% 0:12 ± 0:02% 0:12 ± 0:01% 0:16 ± 0:03%
Non-HP 99:4 ± 0:1% 98:6 ± 0:1% 99:2 ± 0:1% 99:6 ± 0:1% 98:0 ± 0:1% 0:12 ± 0:03% 0:11 ± 0:01% 0:12 ± 0:02%
p value 0.7 0.6 0.7 0.7 0.4 0.7 0.6 0.2
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MSCs with HP was significantly higher compared to that
expressed in CV-MSCs with non-HP after ischemic stimulus
(Figures 5(a) and 5(b)).
3.4. HP Enhanced Angiogenic Growth Factor Release of
CV-MSCs under Ischemic Stimulus. VEGF, BDNF, and
HGF play important roles in angiogenesis [65–68]. In this
study, the ELISA test was performed to determine the
angiogenic growth factor release of CV-MSCs. For the
effect of the hypoxic condition on the growth factor
release of CV-MSCs, the results showed that the release
of VEGF and HGF from CV-MSCs cultured in D5 media
were significantly higher in the hypoxic condition
compared to the normoxic condition and that there was
no significant difference for BDNF release (Figure 6(a)).
For the effect of HP on the growth factor release of
CV-MSCs cultured under ischemic stimulus for 24 h, the
results showed that the release of VEGF and HGF by
CV-MSCs in the HP group was significantly higher
compared to that in the non-HP group and that BDNF
could not be determined in either HP or non-HP groups
(Figure 6(b)).
A BNon-HP HP
μm50
(a)
Caspase-3
Non-HP HP
1.5
1.0
0.5
0.0
Re
la
tiv
e 
ap
op
to
tic
 ra
te
⁎
(b)
Non-HP HP
200
150
100
0
50
Ce
ll 
su
rv
iv
al
 (%
 o
f n
on
-H
P)
MTS assay
⁎
(c)
Figure 4: HP reduced the apoptosis of CV-MSCs after ischemic stimulus. Representative microphotographs taken by light microscopy (a),
caspase-3 activity (b), andMTS assay (c) of CV-MSCs with HP or CV-MSCs with non-HP after ischemic stimulus for 24 h. Data are expressed
as mean ± standard deviation: ∗p < 0:05 (n = 4).
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Figure 5: Effects of HP on CV-MSC biological functions after ischemic stimulus. Western blot analysis of AKT (60 kDa), p-AKT (60 kDa),
and GAPDH (36 kDa) expressed in CV-MSCs with HP or CV-MSCs with non-HP (a) after ischemic stimulus for 24 h. Quantification and
correlative statistical analysis (b). Data are expressed as mean ± standard deviation: ∗p < 0:05 (n = 4).
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3.5. HP Enhanced the Proangiogenic Properties of CV-MSCs
under Ischemic Stimulus. The conditioned media collected
from CV-MSCs with HP or CV-MSCs without HP cultured
in ischemic stimulus for 24 h were used for angiogenic prop-
erty evaluation. The MTS assay results showed that survival
of HECFCs cultured in the conditioned media collected from
CV-MSCs with HP was significantly enhanced compared to
the survival of HECFCs cultured in the condition media
collected from CV-MSCs without HP, and viable cell num-
bers in both groups decreased over time (Figure 7(a)). The
migration and tube formation results showed that the condi-
tioned media collected from CV-MSCs with HP significantly
improved HECFCmigration (Figures 7(b) and 7(c)) and tube
formation (Figures 7(d) and 7(e)) compared to the condition
media collected from CV-MSCs without HP.
4. Discussion
Fetal diseases, which can be devastating and burdensome
for afflicted children and their families, have attracted much
attention in recent decades [69]. Fetal surgery has
progressed and been performed as an effective method of
therapy for select fetal diseases [70, 71]. Stem cell-based
therapy has emerged as a promising area of research to
enhance treatment for a variety of diseases [72, 73] and
has been used extensively to augment existing in utero
surgical techniques for fetal diseases [74, 75]. To further
promote the clinical application of stem cell-based therapy
in fetal medicine, practical approaches must be established
to overcome the general issues associated with cell therapy,
such as limited ex vivo expansion capacity, low multipotent
differentiation ability, inflammatory reactions, immunosup-
pression, and low cell survival and engraftment. Autologous
fetal stem cells isolated from fetal tissues, such as placenta
and amniotic fluid, possess an intermediate phenotype
between embryonic and adult cells, multipotent differentia-
tion ability, anti-inflammatory properties, and low immu-
nogenicity that make them an ideal candidate for fetal
regenerative medicine [76, 77]. Hence, cell survival and
engraftment after transplantation is a major challenge to
the success of in utero stem cell transplantation.
HP refers to the exposure of cells to a moderate hypoxic
environment that results in a resistance to subsequent
severe ischemic damage for cells. HP has been shown to
protect and improve MSC functions after transplantation
[78–80]. In this study, we used 1% oxygen for CV-MSC
preconditioning and simulated an ischemic environment
to mimic the low oxygen concentration in the fetal environ-
ment and the further decrease in local oxygen concentra-
tion present after cell transplantation [81, 82]. The results
of cell viability and alterations in nuclear morphology
showed HP protected CV-MSCs from ischemic damage.
HP has also been demonstrated to increase the expression
of endogenous regenerative factors in stem cell therapy
[83–85]. The AKT pathway is essential for cell survival, as
activated AKT influences many factors involved in apoptosis,
either by transcription regulation or by direct phosphoryla-
tion [86]. In this study, we demonstrated that the activated
form of AKT, phosphorylated-AKT, expressed in CV-MSCs
with HP is significantly higher compared to that expressed
in CV-MSCs without HP. These results further support our
previous results that HP significantly reduces CV-MSC
apoptosis under ischemic stimulus. Previous studies have
demonstrated that MSC transplantation provides many
benefits for the treatment of various diseases [87–89]. One
advantage is that they secrete a variety of cytokines that exert
general protective and regenerative effects in vivo, such as
immunomodulation and tissue regeneration [90, 91]. HP
has been confirmed to enhance the paracrine effects of MSCs
and has also been applied for several diseases [92]. Our pre-
vious work showed that CV-MSCs robustly secrete growth
factors, cytokines, and angiogenic proteins, such as VEGF,
BDNF, and HGF [39]. In this study, we evaluated the effect
of HP on CV-MSC secretion and demonstrated that secre-
tion of several cytokines related to vascular protection, such
as VEGF and HGF, was significantly higher in the HP group,
compared to the non-HP group under ischemic stimulus.
These results indicate that HP of CV-MSCs could effectively
promote tissue repair and formation of new blood vessels in
the surrounding tissue, which is consistent with previous
studies of different types of MSCs [92, 93]. According to
the results, we also found that the environmental nutrition
level was critical for the release of BDNF which is another
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Figure 6: Growth factor release of CV-MSCs in hypoxic condition and effect of HP on growth factor release of CV-MSCs under ischemic
stimulus. Effect of hypoxic condition on growth factor release of CV-MSCs (a). Effect of HP on growth factor release of CV-MSCs
cultured under ischemic stimulus for 24 h (b). Data are expressed as mean ± standard deviation: ∗p < 0:05 (n = 4).
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angiogenic growth factor that can promote endothelial cell
survival and induce angiogenesis in ischemic tissues [68].
Regenerated tissues of a clinically relevant size need a
robust vascular network to supply nutrients and oxygen.
To supply all cells with sufficient nutrients, and to
successfully connect the regenerated vasculature to the
existing vasculature, the newly formed vascular network
needs to be highly organized [94, 95]. VEGF is a key
contributor in the formation of new blood vessels, which
can induce growth of preexisting (angiogenesis) or de novo
vessels (vasculogenesis) and is therefore key for embryonic
development and vessel repair [65, 66]. HGF is a potent
angiogenic factor that stimulates endothelial cell motility
and growth, which also enhances VEGF-induced angiogen-
esis [67]. Based on these findings, we evaluated the effect of
HP on EC functions and showed that HP significantly
enhances the proangiogenic properties of CV-MSCs under
ischemic stimulus, by improving the secretion of VEGF
and HGF. Hence, transplanting CV-MSCs primed with
HP represents an ideal approach for fetal tissue engineering
and treatment of various fetal diseases.
5. Conclusions
In this study, we demonstrated that HP significantly enhances
the survival, secretion of bioactive factors, and proangiogenic
capacity of CV-MSCs under ischemic stimulus. Based on our
previous work demonstrating that early gestation CV-MSCs
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Figure 7: Effects of HP on CV-MSC proangiogenic properties under ischemic stimulus. After ischemic stimulus for 24 h, conditioned media
collected from CV-MSCs with HP significantly enhanced HECFC survival (a), migration (b, c), and tube formation (d, e) compared to
conditioned media collected from CV-MSCs without HP. The data were quantified, and statistical analyses were performed. Data are
expressed as mean ± standard deviation: ∗p < 0:05 (n = 4).
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are an ideal cell source for fetal tissue engineering and disease
treatment, this study successfully developed an optimal and
practical approach to expand and improve the efficiency of
applying CV-MSCs for fetal tissue engineering and treatment
of various fetal diseases.
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